Pillar Biosciences Enters into Strategic Licensing Agreement for MSK’s OncoKB™ Precision Medicine Knowledgebase

Agreement aims to enhance Pillar’s PiVAT® bioinformatics platform with downstream reporting capabilities.

NATICK, Mass., Jan. 7, 2025 /PRNewswire/ — Pillar Biosciences, Inc. has entered into a strategic five-year licensing agreement with Memorial Sloan Kettering Cancer Center (MSK) for its proprietary OncoKB^™ precision medicine knowledgebase.

OncoKB^™ is the first somatic human variant database to receive FDA recognition. It contains information about the biological effects and possible treatment implications of specific cancer gene alterations. 

The strategic licensing agreement enables immediate extension of the capability of Pillar Biosciences PiVAT® bioinformatics platform for seamless patient genomic reporting through linkage to OncoKB^™.  

“Our PiVAT® secondary genomics analysis platform was purpose built for our SLIMamp® chemistry to enable the most accurate genomic calling for our kitted RUO and IVD products,” said ShiPing Zou, Senior Director of Global Product Management, Pillar Biosciences. “While Pillar’s panels are agnostic to which tertiary reporting our clients have implemented, it is important we ensure that downstream genomic reporting is not a bottleneck to assay validation and implementation and that we continue to provide timely access to actionable information to our customers and the patients they serve.”

About Pillar Biosciences

Pillar Biosciences is the leader in Decision Medicine™, which is the utilization of highly accurate and sensitive next-generation sequencing (NGS) testing technology to generate data that optimizes selection of precision therapies for cancer patients, from tumor profiling to therapy selection, and recurrence monitoring. Pillar’s NGS testing solutions are powered by its proprietary SLIMamp® and PiVAT® technologies, helping to localize the testing process, reduce diagnostic costs and improve access and efficiency of complex NGS testing for clinicians, prescribers, and patients globally. The company has more than 20 NGS testing kits available in IVD or RUO formats, with multiple panels in various stages of development. Pillar Biosciences has operations in Natick, MA. For more information visit pillarbiosci.com and connect with us on LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/pillar-biosciences-enters-into-strategic-licensing-agreement-for-msks-oncokb-precision-medicine-knowledgebase-302338477.html

SOURCE Pillar Biosciences, Inc.